
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is a biopharmaceutical company specializing in developing therapies for mental health disorders, with a focus on its proprietary synthetic psilocybin formulation, COMP360. It recently reported positive results from two Phase 3 trials for COMP360 in treatment-resistant depression (TRD), and has a planned meeting with the FDA to discuss its new drug application (NDA) filing strategy. The company is also conducting trials for COMP360 in other indications, such as post-traumatic stress disorder (PTSD) and anorexia nervosa, and has secured significant funding and partnerships. With promising data and a solid pipeline, Compass Pathways is positioned for success in the rapidly growing field of psychedelic therapeutics.
Bears say
Compass Pathways is facing potential competition in the future and its clinical trials, while successful, have not shown strong enough results to convince the FDA to approve the treatment yet. Additionally, their drug's safety profile is clean, but lacks significant efficacy results, making it a less attractive option for patients and physicians. Finally, while the company has shown some diversity on the management and board levels, there is still room for improvement in terms of representation.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares